Replies to post #26513 on CuraScientific Corp (CSTF)

[Witty159]

Agreed.

We’re dealing with an OTC company. You want to see skin in the game. I did some digging on the IR firm, and they look to be entirely legitimate.

The BNOW board is also getting more active on their Twitter with shareholder questions, so I’m thinking we’re nearer to the end than the beginning with regards to material releases.

[JohnnyThundersLAMF]

...being paid in shares opposed to salary.

They obviously don’t have the cashflow to pay salaries. That just means more shares will be issued in lieu of salary ($362,000 worth annually plus interest to the CEO and a Director) and dumped on the market along with the convertible preferred stock and toxic notes. That’s not a positive.

some overlaps between BNOW and a couple of other stocks

There’s a lot more than just some overlaps. Read my previous posts on all the connections to Simlatus and Brewbilt.

overlap is a result of using the same consultants to go public etc

Correct. That ‘consultant’ is convicted penny stock fraudster Scott Sand. Boon shareholders already paid Sand’s shell LLC C Group at least $3 million for an “exclusive” distribution and licensing agreement and received nothing in return. Plus there’s the 16 toxic notes issued to Sand’s Optempus / C Group.

terms of the convertible notes appear fairly standard

Correct again. Extremely unfavorable terms that are toxic to common shareholders are fairly standard. Those terms also tend to result in bankruptcy and shareholder wipeouts. Very lucrative for the funders though.

Hopefully the uplist is near and they will be able to obtain more favorable funding

Tiny companies obtain traditional loans and financing all the time. There is nothing preventing Boon from doing the same. Unless maybe further enriching toxic funders and cashing out using convertible preferred stock is the whole point?

[Madmen333]

Can I know what questions you asked IR and what the responses were ?